Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 2
2017 1
2019 1
2020 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.
Garzon R, Savona M, Baz R, Andreeff M, Gabrail N, Gutierrez M, Savoie L, Mau-Sorensen PM, Wagner-Johnston N, Yee K, Unger TJ, Saint-Martin JR, Carlson R, Rashal T, Kashyap T, Klebanov B, Shacham S, Kauffman M, Stone R. Garzon R, et al. Blood. 2017 Jun 15;129(24):3165-3174. doi: 10.1182/blood-2016-11-750158. Epub 2017 Mar 23. Blood. 2017. PMID: 28336527 Free PMC article. Clinical Trial.
Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies.
Hing ZA, Fung HY, Ranganathan P, Mitchell S, El-Gamal D, Woyach JA, Williams K, Goettl VM, Smith J, Yu X, Meng X, Sun Q, Cagatay T, Lehman AM, Lucas DM, Baloglu E, Shacham S, Kauffman MG, Byrd JC, Chook YM, Garzon R, Lapalombella R. Hing ZA, et al. Leukemia. 2016 Dec;30(12):2364-2372. doi: 10.1038/leu.2016.136. Epub 2016 May 20. Leukemia. 2016. PMID: 27323910 Free PMC article.
Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study.
Bhatnagar B, Zhao Q, Mims AS, Vasu S, Behbehani GK, Larkin K, Blachly JS, Blum W, Klisovic RB, Ruppert AS, Orwick S, Oakes C, Ranganathan P, Byrd JC, Walker AR, Garzon R. Bhatnagar B, et al. Leuk Lymphoma. 2020 Feb;61(2):387-396. doi: 10.1080/10428194.2019.1665664. Epub 2019 Sep 23. Leuk Lymphoma. 2020. PMID: 31545113 Free PMC article. Clinical Trial.
XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus.
Ranganathan P, Kashyap T, Yu X, Meng X, Lai TH, McNeil B, Bhatnagar B, Shacham S, Kauffman M, Dorrance AM, Blum W, Sampath D, Landesman Y, Garzon R. Ranganathan P, et al. Clin Cancer Res. 2016 Dec 15;22(24):6142-6152. doi: 10.1158/1078-0432.CCR-15-2885. Epub 2016 Jun 29. Clin Cancer Res. 2016. PMID: 27358488 Free PMC article.
Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia.
Ranganathan P, Yu X, Santhanam R, Hofstetter J, Walker A, Walsh K, Bhatnagar B, Klisovic R, Vasu S, Phelps MA, Devine S, Shacham S, Kauffman M, Marcucci G, Blum W, Garzon R. Ranganathan P, et al. Blood. 2015 Apr 23;125(17):2689-92. doi: 10.1182/blood-2014-10-607648. Epub 2015 Feb 25. Blood. 2015. PMID: 25716206 Free PMC article.